UNIGE document Scientific Article
previous document  unige:110675  next document
add to browser collection
Title

Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study

Authors
Msihid, Jérôme
Zilberstein, Moshe
Paccard, Caroline
Lin, Yong
Graham, Neil M H
Boyapati, Anita
Published in RMD Open. 2018, vol. 4, no. 1, p. e000607
Abstract Interleukin-6 (IL-6) orchestrates formation of an inflammatory pannus, leading to joint damage in rheumatoid arthritis (RA). Sarilumab is a human monoclonal antibody blocking the IL-6Rα. In TARGET (NCT01709578), a phase 3 study in adults with moderate-to-severe RA and inadequate response or intolerance to tumour necrosis factor inhibitors, subcutaneous sarilumab 200 mg or 150 mg every 2 weeks (q2w) plus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) significantly reduced disease activity versus placebo plus csDMARDs.
Identifiers
PMID: 29556418
Full text
Article (Published version) (1.1 MB) - public document Free access
Structures
Research group Mécanisme de l'inflammation articulaire (44)
Citation
(ISO format)
GABAY, Cem et al. Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study. In: RMD Open, 2018, vol. 4, n° 1, p. e000607. doi: 10.1136/rmdopen-2017-000607 https://archive-ouverte.unige.ch/unige:110675

224 hits

105 downloads

Update

Deposited on : 2018-11-12

Export document
Format :
Citation style :